Derek Maetzold - Castle Biosciences President CEO, Founder, Director
| CSTL Stock | USD 30.28 0.16 0.53% |
CEO
Mr. Derek J. Maetzold is President, Chief Executive Officer, Founder and Director of Castle Biosciences, Inc. A leader in the biopharmaceutical industry for the past 25 years, Derek Maetzold founded Castle Biosciences in 2007 and has successfully overseen the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, with more in the pipeline. Derek founded the Company after a career of successive leadership roles at Encysive Pharmaceuticals, Schering Corporation, Integrated Communications, Amylin Pharmaceuticals and Sandoz . Derek started in field sales, and has served in roles that span the disciplines of marketing, new product development, business development, and commercialization strategy. Previously, he served as Officer and Vice President, Marketing and Sales, at Encysive Pharmaceuticals. He attended George Mason University, where he received a B.S. in Biology, and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of CaliforniaRiverside. Derek is a published author, and a coinventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. since 2017.
| Age | 62 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 505 South Friendswood Drive, Friendswood, TX, United States, 77546 |
| Phone | 866 788 9007 |
| Web | https://castlebiosciences.com |
Derek Maetzold Latest Insider Activity
Tracking and analyzing the buying and selling activities of Derek Maetzold against Castle Biosciences stock is an integral part of due diligence when investing in Castle Biosciences. Derek Maetzold insider activity provides valuable insight into whether Castle Biosciences is net buyers or sellers over its current business cycle. Note, Castle Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Castle Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Derek Maetzold over two weeks ago Disposition of 299 shares by Derek Maetzold of Castle Biosciences at 34.15 subject to Rule 16b-3 | ||
Derek Maetzold over a month ago Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 28.734 subject to Rule 16b-3 | ||
Derek Maetzold over two months ago Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 29.457 subject to Rule 16b-3 | ||
Derek Maetzold over two months ago Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 30.024 subject to Rule 16b-3 |
Castle Biosciences Management Efficiency
The value of Return On Tangible Assets is estimated to slide to -0.18. The value of Return On Capital Employed is expected to slide to -0.18. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.8 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | CEO Age | ||
| John Hanna | Caredx Inc | 44 | |
| Peter Maag | Caredx Inc | 57 | |
| Hamid Erfanian | Enzo Biochem | 54 | |
| Helmy Eltoukhy | Guardant Health | 45 | |
| Scott Hutton | Biodesix | 52 | |
| Timothy Damadian | Fonar | 60 | |
| John Aballi | Exagen Inc | 39 | |
| Evguenia MBA | Sera Prognostics | 50 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
| Christopher Hall | Personalis | 55 | |
| Keith Sullivan | Neuronetics | 66 | |
| Steven Chapman | Natera Inc | 45 | |
Management Performance
| Return On Equity | 0.0147 | ||||
| Return On Asset | -0.0014 |
Castle Biosciences Leadership Team
Elected by the shareholders, the Castle Biosciences' board of directors comprises two types of representatives: Castle Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Castle. The board's role is to monitor Castle Biosciences' management team and ensure that shareholders' interests are well served. Castle Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Castle Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Toby Juvenal, Vice President of Sales | ||
| Camilla Zuckero, Exec Communications | ||
| Derek Maetzold, President CEO, Founder, Director | ||
| John Abbott, VP Controller | ||
| RN RN, Chief Officer | ||
| Kristen RN, Chief Officer | ||
| Tobin Juvenal, Chief Officer | ||
| Kevin Doman, Vice Sales | ||
| Alice Izzo, Senior Marketing | ||
| Matthew MD, Senior Medical | ||
| Keli Greenberg, VP Resources | ||
| Robert Cook, Senior Development | ||
| Frank Stokes, CFO Treasurer | ||
| Bernhard Spiess, Company Secretary |
Castle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Castle Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0147 | ||||
| Return On Asset | -0.0014 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 599.5 M | ||||
| Shares Outstanding | 28.01 M | ||||
| Shares Owned By Insiders | 3.22 % | ||||
| Shares Owned By Institutions | 94.58 % | ||||
| Number Of Shares Shorted | 1.71 M | ||||
| Price To Earning | 87.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.